Morgan Stanley began coverage on shares of Roche (OTCMKTS:RHHBY - Free Report) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The firm issued an equal weight rating on the stock.
Separately, Sanford C. Bernstein raised Roche to a "strong-buy" rating in a research report on Thursday, January 30th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold".
Read Our Latest Report on RHHBY
Roche Trading Down 0.6 %
RHHBY traded down $0.24 on Wednesday, hitting $41.05. The company had a trading volume of 1,158,538 shares, compared to its average volume of 1,758,382. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86. The company's fifty day moving average price is $37.04 and its 200 day moving average price is $38.34. Roche has a 1-year low of $29.20 and a 1-year high of $42.43.
Institutional Trading of Roche
A number of institutional investors and hedge funds have recently modified their holdings of RHHBY. AlphaMark Advisors LLC bought a new stake in shares of Roche during the third quarter valued at approximately $149,000. Kornitzer Capital Management Inc. KS grew its position in Roche by 1.3% in the third quarter. Kornitzer Capital Management Inc. KS now owns 136,923 shares of the company's stock valued at $5,490,000 after acquiring an additional 1,798 shares during the period. Verity Asset Management Inc. bought a new stake in Roche in the third quarter valued at $253,000. Canopy Partners LLC grew its position in Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company's stock valued at $310,000 after acquiring an additional 344 shares during the period. Finally, Brooklyn Investment Group bought a new stake in Roche in the third quarter valued at $40,000.
About Roche
(
Get Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Read More
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
